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Tears have attracted interest as a minimally-invasive biological fluid from which to assess
biomarkers. Lactoferrin (Lf) and lysozyme (Lys) are abundant in the tear fluid and have
antimicrobial properties. Since the eye is a portal for infection transmission, assessment
of immune status at the ocular surface may be clinically relevant. Therefore, the aim
of this series of studies was to investigate the tear fluid antimicrobial proteins (AMPs)
Lf and Lys as biomarkers of mucosal immune status. To be considered biomarkers of
interest, we would expect tear AMPs to respond to stressors known to perturb immunity
but be robust to confounding variables, and to be lower in participants with heightened
risk or incidence of illness. We investigated the relationship between tear AMPs and
upper respiratory tract infection (URTI; study 1) as well as the response of tear AMPs
to prolonged treadmill exercise (study 2) and dehydration (study 3). Study 1 was a
prospective cohort study conducted during the common cold season whereas studies
2 and 3 used repeated-measures crossover designs. In study 1, tear Lys concentration
(C) as well as tear AMP secretion rates (SRs) were lower in individuals who reported
pathogen-confirmed URTI (n = 9) throughout the observation period than in healthy,
pathogen-free controls (n = 17; Lys-C, P = 0.002, d = 0.85; Lys-SR, P < 0.001, d
= 1.00; Lf-SR, P = 0.018, d = 0.66). Tear AMP secretion rates were also lower in
contact lens wearers. In study 2, tear AMP SRs were 42–49% lower at 30 min−1 h
post-exercise vs. pre-exercise (P < 0.001, d = 0.80–0.93). Finally, in study 3, tear
AMPs were not influenced by dehydration, although tear AMP concentrations (but not
secretion rates) displayed diurnal variation. We conclude that Lf and Lys have potential
as biomarkers of mucosal immune competence; in particular, whether these markers are
lower in infection-prone individuals warrants further investigation.
Keywords: antimicrobial proteins (AMPs), common cold, contact lenses, dehydration, endurance exercise,
infection risk, upper respiratory tract infection (URTI)
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INTRODUCTION
Tears are an attractive medium from which to assess biomarkers.
For several decades, tear biomarkers have been used as a tool to
understand the mechanisms and consequences of ocular disease.
However, in recent years, interest in the tear fluid has increased as
a source of biomarkers for the detection of systemic disease and
to assess neuroendocrine responses to stress (1–3). Evaluation
of systemic immune status using the tear fluid may be relevant
because transmission of viral upper respiratory tract infections
(URTI) can occur at the ocular surface (4, 5), and transmission of
pathogens via self-inoculation at the eyes or nose may even occur
more readily than oral transmission (6). These observations
suggest that it is important to maintain an effective immune
defense at the eye to prevent both ocular and systemic infections,
and also highlight the ocular surface as a site of clinical relevance
for immune-monitoring applications.
Lactoferrin (Lf) and lysozyme (Lys) are two of the most
abundant antimicrobial proteins (AMPs) in tear fluid (7) and play
important roles in innate mucosal defense. Lf is an iron-binding
glycoprotein that exhibits a multitude of antimicrobial activities,
including antiviral activity against pathogens responsible for
common URTIs such as respiratory syncytial virus (8) and
influenza (9), as well as sequestration of iron to prevent
bacterial growth and binding of Gram-positive and Gram-
negative bacteria (10). Lys is a bacteriolytic enzyme discovered by
Fleming (11) that exhibits antimicrobial activity predominantly
by attacking the bacterial cell wall. Synergistic effects of Lys
and Lf in neutralizing bacterial pathogens have also been
reported (12). Besides the direct actions of AMPs against
microorganisms, Lf and Lys may also play a role in modulating
host immune responses to infections, for example by exerting
anti-inflammatory effects at mucosal surfaces (13, 14). It is
notable that the specific targets of Lys are typically bacteria,
yet URTIs are most typically of viral origin (15). However,
the broader role of Lys in immune modulation provides a
rationale for its involvement in defense against a wider spectrum
of pathogens.
For almost three decades, salivary secretory IgA (s-IgA)
has been a favored, convenient biomarker of immune status,
although an abundance of both positive and negative results
as well as high biological variability has led its validity to be
questioned (16). Salivary AMPs have also been identified as
biomarkers of interest for the assessment of innate immune
status and susceptibility to URTI (17). One study reported
lower salivary Lys and Lf concentrations in elite rowers during
5 months’ heavy training, compared to sedentary individuals
(18), but to date no relationship between salivary Lf or Lys
and susceptibility to URTI has been reported. Salivary Lys has,
however, been linked to bacterial respiratory infection incidence
in a clinical population; in a cohort of patients with chronic
obstructive pulmonary disease, Taylor et al. (19) reported lower
salivary lysozyme concentrations in infection-prone patients
compared to those who reported fewer episodes of infection.
Salivary Lys may also be associated with occupational stress (20),
while salivary Lf is responsive to a passive laboratory stressor
in tandem with increased vagal tone and modest increases in
sympathetic activity (21). Taken together, these observations
suggest that, at least in saliva, Lf and Lys secretion is sensitive to
changes in autonomic activity as well as stressors such as physical
activity, and may also have a prophylactic effect in the prevention
of infection. Regardless, issues with saliva sampling remain, not
least because saliva is the pooled product of secretions from
multiple glands, each with its own autonomic innervation and
regulation, where the secretions from the major glands differ
substantially in their composition of proteins (22, 23).
The tear film is comprised of three layers, an inner mucin
layer, middle aqueous layer and outer lipid layer. The outer lipid
layer is secreted by the Meibomian glands and serves to prevent
rapid evaporation of the aqueous layer. The aqueous component
is predominantly secreted by the main and accessory lacrimal
glands with minor contributions from corneal and conjunctival
cells. Conjunctival goblet cells are the major contributor to
the mucin layer. Lf and Lys are found in the middle aqueous
component and are constitutively synthesized and secreted by
lacrimal gland acinar cells at concentrations around 1–3mg·ml−1
(7, 24), each comprising around 20–30% of total protein in
basal and reflex tears (25). Basal tear flow rate has been
reported at around 1 µL·min−1 but can increase more than
50-fold upon stimulation (7, 26). Lacrimal gland regulation
occurs in three broad steps: activation of afferent nerves in
the cornea and conjunctiva leads to stimulation of efferent
autonomic nerves, which in turn activates cellular signaling
pathways in the acinar and duct cells that lead to secretion of
proteins, electrolytes and water (27). Tears have therefore been
described as the final output of the lacrimal functional unit,
integrating the major glands and interconnecting innervation
(28). Lacrimal gland secretory activity is also modulated by
steroid hormones, oxidative stress and inflammation (29–31).
Pro-inflammatory cytokines; in particular IL-1β and TNF-A; can
inhibit neurally-mediated lacrimation and have been implicated
in several diseases characterized by disordered lacrimal gland
secretory activity, such as dry eye disease and Sjögren’s syndrome
(31, 32). As well as providing a mechanism by which disordered
lacrimation can arise, these observations suggest that lacrimal
gland secretory activity may be sensitive to acute stressors
(such as prolonged exercise or psychological stress) that exhibit
brief, systemic immunomodulatory effects. This may enable the
integrity of antimicrobial defense at the ocular surface to be used
as a non-invasive indicator of the influence of daily life stressors
on global immune status.
Considering that tear sampling is minimally-invasive in
nature, and that advances in nanotechnology may permit
development of wearable sensors in contact lenses (33), we
suggest that there is potential for tear biomarkers to supersede
salivary markers for monitoring applications in athletes, military
personnel or other field-based scenarios where blood sampling
is impractical. Indeed, we recently demonstrated that s-IgA in
tear fluid is reduced prior to episodes of URTI (34) and is also
temporarily depressed by prolonged, moderate-intensity exercise
(34) and brief psychological stress (35). However, the potential
of other tear biomarkers as diagnostic or monitoring tools for
immune- or health-status remains relatively unexplored. Given
that Lf and Lys are abundant in tears and that the eye is a clinically
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relevant site at which to evaluate host defense, investigation
of the relationship between tear AMPs and URTI susceptibility
is warranted.
The purpose of this series of studies was therefore to
investigate the utility of tear AMPs to evaluate mucosal immune
competence and URTI susceptibility in otherwise healthy, active
individuals. First, to investigate whether tear AMPs could
provide a clinically relevant measure of immune status, in a
prospective cohort study we set out to investigate whether any
differences in tear AMPs could be observed in participants
who reported URTI vs. those who did not, and also whether
any perturbations in tear AMPs arose in the days prior to
URTI. Next, we investigated tear AMP responses to prolonged
exercise, known to perturb mucosal immunity (36, 37), and
dehydration, which has been commonly cited as a confounding
variable that may decrease flow rates of mucosal fluids but does
not affect systemic immunity (34, 38). To our knowledge tear
AMP responses to these physiological stressors have not been
previously investigated, thus, the purpose of studies 2 and 3 was
to investigate tear AMP responses to prolonged exercise and
dehydration. We postulated that if tear AMPs respond to each
stressor as expected, this will not only indicate a direct effect (or
no effect) of the stressor on key components of mucosal immune
defense, but also improve confidence in tear AMPs as minimally-
invasive biomarkers of systemic immunity. Collectively, these
studies aimed to evaluate the utility of tear Lf and Lys as novel
biomarkers of URTI susceptibility.
MATERIALS AND METHODS
Overview
This investigation is an extension of a previous publication.
Herein we present novel analyses of Lf and Lys from tear samples
that have been previously been used to evaluate the utility of tear
secretory IgA as a biomarker of URTI risk (34).
To evaluate the utility of Lf and Lys as biomarkers of immune
status, we employed a multi-study approach. In study 1, we
evaluated the utility of Lf and Lys to predict URTI in a cohort
of recreationally active individuals during the common cold
season. In study 2, we investigated the response of tear Lf and
Lys to prolonged exercise. Finally, in study 3, we investigated
the influence of hydration status on tear Lf and Lys. All studies
received approval from the Bangor University School of Sport,
Health and Exercise Sciences Ethics Committee (application
numbers S/PhD08-14/15, S/PhD11-12/13 and S/PhD09-13/14).
Participants provided written, informed consent before taking
part, and all test procedures were conducted in accordance with
the Declaration of Helsinki.
Study 1
Participants
Forty participants (26 men and 14 women, age 22 ± 4 y,
mean ± SD) were recruited to take part in the study during
the fall common cold season. Participants were university staff
and students, and the study took place within the first 6 weeks
of the academic semester, a period where anecdotal reports
suggest that URTI is highly prevalent in universities. Due to
drop-outs and non-compliance, 33 participants completed the
study. Participants reported that they had been free from upper
respiratory symptoms (URS) for a month before participating,
did not have any underlying health conditions (including no
recent diagnosis or test for mononucleosis within 1 y), and were
not taking medication known to influence immune indices. Eight
participants wore contact lenses. Participants did not eat or drink
(besides water) 1 h prior to tear sample collection.
Experimental Procedures
Detailed experimental procedures for this study have been
published previously (34). Briefly, participants completed a 3-
week URS-monitoring protocol. Participants provided a tear
sample each week and reported URS daily online using the
Jackson Common Cold Scale (39). The scale comprises a global
question “Do you think you are suffering from a common cold
today?” followed by eight symptom items scored either 0 (not
at all), 1 (mild), 2 (moderate) or 3 (severe). If participants
answered yes to the global question or reported a symptom
score ≥ 6 for two consecutive days, they were deemed to
have reported an episode of upper respiratory illness (URI)
and were contacted by investigators and asked to report to the
laboratory within 48 h.When participants with URI arrived at the
laboratory we collected a tear sample as well as nasopharyngeal
and throat swabs according to standard procedures (40). Swabs
were used at a later date for laboratory detection of common
viral and bacterial pathogens using real-time polymerase chain
reaction methods as previously described (34). Participants that
reported an episode of URI were asked to continue to report
their symptoms daily until they had been free from URI for
4 weeks. Participants who did not report URI provided final
tear samples as well as nasopharyngeal and throat swabs after
3 weeks of URS monitoring. To control for diurnal variation
between sampling in the same individual, samples were collected
after 10:00 to avoid rapid changes in tear composition that
may occur in the period after waking. Participants provided
subsequent samples as close to the original sampling time as
possible and within a maximum 3h window. All participants
completed their 3-week URS monitoring period within a 6-week
window in September-October.
Study 2
Participants
Thirteen healthy, recreationally active male participants (age 23
± 5 y, height 1.79 ± 0.08m, BM 79 ± 9 kg, VO2peak 52.8 ±
5.6 mL·kg−1 · min−1) took part in the study. Participants were
non-smokers, who had not taken prescription medication or
used dietary supplements for 1 month before taking part in the
study and did not wear contact lenses. For 24 h before each trial,
participants were asked to refrain from caffeine, alcohol, over-
the-counter medication and heavy exercise. Participants reported
that they had been free from URS for 1 week before each trial.
Preliminary Tests
During the preliminary visit, participants completed a ramped
treadmill exercise test to determine VO2peak according to a
protocol detailed in a previous study (36). Following the
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incremental test, a treadmill speed to elicit ∼60% VO2peak was
interpolated from the integrated submaximal running stages in
the ramped test using linear regression. After participants had
rested for 30min, this speed was then verified by measuring
steady-state VO2 during the last minute of a 5min exercise bout,
with treadmill speed adjusted and the exercise bout repeated
where necessary.
Experimental Procedures
Participants completed two experimental trials in a randomized,
cross-over design, in accordance with a protocol described
previously (34). For each trial, participants reported to the lab
at 07:30 and were provided with a standardized breakfast and a
fluid allowance of 35mL·kg−1 ·day−1 pro rata for the pre-exercise
period. During the exercise trial (EX), participants completed a
120min treadmill run at∼65% VO2peak in temperate conditions;
a duration and intensity previously shown to perturb in vivo
immunity (36). During the rested control trial, participants
rested in an upright seated position for 120min (REST). EX
or REST commenced at 11:00. During EX only, participants
reported Borg’s rating of perceived exertion every 5min and
we collected 60 s expired gas samples at 10min intervals for
VO2 assessment. Expired gas was collected into Douglas bags
and analyzed for O2, CO2 (Servomex 5200, Crowborough, UK),
volume and temperature (Harvard Apparatus, Edenbridge, UK),
enabling derivation of VO2 using the Douglas bagmethod. As the
speed was fixed for the 120min exercise period, actual exercise
intensity during the 120min rose from 62.7 ± 6.4% VO2peak at
10min to 67.9 ± 5.4% VO2peak at 110min due to VO2 drift.
Heart rate (HR) was recorded at 5min intervals throughout the
120min exercise/rest period in both trials. HR and Borg data
have been reported previously (34). During the 120min run in
EX, participants were provided with 3 mL·kg−1·h−1 plain water
to offset fluid losses through sweating; during REST and non-
exercising periods in EX, fluid intake was provided at a rate of 35
mL·kg−1·day−1. Tear samples were collected at five time points
during EX: pre-exercise, post-exercise, 30min post-exercise, 1 h
post-exercise and 24 h post-exercise, and at the equivalent time
points during REST.
Study 3
Participants
Thirteen male participants (age 23 ± 4 y, height 1.81 ± 0.05m,
body mass (BM) 80 ± 10 kg, VO2peak 56.4 ± 7.8 mL·kg
−1 ·
min−1) visited the laboratory on three occasions. Participants
were non-smokers and none wore contact lenses. Participants
avoided caffeine, alcohol, over-the-counter medication and
strenuous exercise for 24 h before each trial. No episodes of
upper respiratory symptoms (URS) were reported by participants
during the week preceding each visit.
Preliminary Visit
On the first visit, participants completed a ramped maximal
treadmill running test to determine their VO2peak, according
to a test procedure previously described (34). The ramped test
was followed by a 30-min treadmill walk at 4% gradient in an
environmental chamber set to 40◦C and 40% relative humidity
(RH). The walking speed was interpolated from the ramped
protocol and estimated to elicit 50% VO2peak (mean: 6.6, range:
5.5–7.5 km·h−1). Nude body mass loss (BML) during the 30-
min exercise bout was used to calculate a sweat rate for each
participant (BML/exercise time in minutes). We then used the
sweat rate to estimate the total walking duration required to elicit
3% BML for the main experimental trials.
Experimental Procedures
On the second and third visits, participants completed a
dehydration (DEH) or euhydrated control (EUH) trial in a
randomized, crossover design. Each trial lasted 27.5 h, from 08:00
on day 1 until 11:30 the following day. Standardized meals
were provided at fixed time points throughout the trials. On
the morning of day 1, participants were provided with fluids at
a rate of 40 mL·kg−1 · day−1 until 14:00. Beginning at 14:00
on day 1, participants performed three bouts of exercise in
the chamber in the same environmental conditions as used in
the preliminary test (40◦C, 40% RH). The duration of each
exercise bout was determined based on the sweat rate measured
during the first test and estimated to elicit 1% body mass loss.
Participants rested for 30min outside the chamber (∼ 18◦C)
in between exercise bouts. During DEH, participants received
no fluids, whereas during EUH participants were provided with
a volume of plain water equivalent to 1% BM during each
bout. Core temperature was monitored continuously during
the dehydration protocol using a rectal thermistor, to ensure
participants’ core temperatures did not exceed 39◦C. After three
exercise bouts, participants remained in the laboratory overnight.
During this period, participants received a standardized evening
meal at 18:30 and engaged in sedentary activities with restricted
fluid intake (DEH: 4 mL·kg−1 · day−1) or control fluid intake
(EUH: 40 mL·kg−1 · day−1) until they were permitted to sleep
between 23:00 and 07:30. Tear samples as well as plasma samples
for determination of osmolality were collected at four time
points: 14:00 day 1 (0% BML), ∼16:30 day 1 (∼2% BML),
08:00 day 2 (∼3% BML) and 11:30 day 2 (∼0% BML). A
standardized breakfast was given at 08:30 on day 2, coinciding
with commencement of the rehydration period. BML and plasma
osmolality data have been presented elsewhere (34).
Tear Sample Collection, Handling and
Analysis
Tear samples of at least 0.5 µL volume were collected from the
inferior marginal tear strip into 10 µL glass microcapillary pipets
using a technique previously described (34). Collection time was
recorded by a second operator and the tear flow rate calculated
as collection volume divided by collection time, assuming the
density of tear samples to be 1.00 g·mL−1. Samples were then
diluted 100x in phosphate-buffered saline and stored at −80◦C
until analysis. Commercially available ELISA kits (AssayPro, St.
Charles, MO, USA) were used to determine concentrations of
Lf and Lys in tear samples (mean intra-assay CVs: Lf 4.4%,
Lys 4.8%).
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Statistical Analysis
Statistical analyses were performed using a combination of the
Excel (Office Professional 2016, Microsoft, RedmondWA, USA),
SPSS (v20, IBM, Chicago, IL, USA) and Prism (v7, GraphPad,
San Diego, CA, USA) software packages. Data were checked
for normality using the Shapiro-Wilk test and Q-Q normality
plots. Where variables were log-normally distributed, statistical
analyses were performed on data transformed as follows to avoid
negative skew: xtransformed = log10(x+1).
In study 1, t-tests were used to determine group-wise
effects for normally distributed variables; Welch’s correction
was applied in cases of unequal variance. One-way repeated
measures ANOVA was used to compare within-subject effects.
Results of studies 2 and 3 that employed repeated-measures
crossover designs were analyzed using two-way repeated-
measures ANOVA in SPSS. In cases where sphericity was
violated, the Greenhouse-Geisser correction was applied and
corrected degrees of freedom are displayed. Cohen’s d effect
sizes and/or percentage differences were calculated for key
outcomes, on transformed data where applicable, and interpreted
as follows: ≥ 0.2 = “small,” ≥ 0.5 = “medium,” ≥ 0.8
= “large.” Data are presented as mean ± SD for normally
distributed data and geometric mean ± SD factor for log-
normally distributed data. Normally distributed variables are
displayed using linear axes and log-normally distributed variables
on log-axes.
RESULTS
Study 1: Relationship Between Tear AMPs
and URTI Susceptibility
Eleven of 33 participants reported an episode of URI, of
which nine were associated with a respiratory pathogen. Of
the 22 participants who did not report URI, five were carrying
respiratory pathogens at week 3. Therefore, nine participants
with “URTI” (four contact lens wearers and five non-contact lens
wearers), two “URS” participants with symptoms but negative
virology (non-contact lens wearers), 17 “healthy” participants
(three contact lens wearers and 14 non-contact lens wearers), and
five “asymptomatic carriers” (positive virology but no symptoms,
no contact lens wearers) were included in the analysis. Within
the largest, healthy group, seven participants provided morning
samples (10:00–12:00) and 10 afternoon (14:00–16:30) samples.
Sub-analysis of the healthy group at two time points (pre-
and post-monitoring) revealed no significant diurnal variation
in AMP concentrations or secretion rates between participants
sampled in the morning vs. afternoon (all P > 0.05, Table 1).
Each of the other groups included samples taken in bothmorning
and afternoon (URTI: three morning, six afternoon; URS: one
morning, one afternoon; asymptomatic carriers: three morning,
two afternoon.)
Tear Lys concentration (C) and secretion rate (SR) were
lower in participants with URTI (in samples collected during
TABLE 1 | Tear lysozyme (Lys) and lactoferrin (Lf) in Healthy participants who provided samples in the morning (7 participants) vs. afternoon (10 participants) at two time
points.
Variable Morning (n = 14) Afternoon (n = 20) t (df) P d
Lys-C mg·mL−1 0.56 ± 2.05 0.74 ± 1.97 1.19 (31) 0.24 0.43
Lys-SR µg·min−1 3.04 ± 3.10 2.10 ± 2.83 1.04 (31) 0.30 0.35
Lf-C mg·mL−1 2.90 ± 1.89 3.15 ± 2.26 0.61 (32) 0.54 0.09
Lf-SR µg·min−1 15.77 ± 2.84 8.56 ± 3.53 1.53 (32) 0.14 0.52
One sample in the morning group was out of range of the assay for Lys-C and not included in the analysis of Lys. Data are geometric mean ± geometric SD factor. C, concentration;
SR, secretion rate; t, t-statistic; df, degrees of freedom; d, Cohen’s d effect size.
TABLE 2 | Comparison of tear lysozyme (Lys) and lactoferrin (Lf) during pathogen-confirmed URTI (n = 9, samples collected during URTI) vs. participants who remained
healthy throughout the monitoring period (n = 17, post-monitoring samples, pathogen-free at time of sampling), as well as all participants with symptoms (URTI + URS, n
= 11) vs. all those without symptoms (healthy + asymptomatic carriers, n = 22).
Variable URTI Healthy t (df) P d
Lys-Ca mg·mL−1 0.39 ± 0.17 0.96 ± 0.63 3.43 (18.5) 0.003 1.11
Lys-SRb µg·min−1 0.83 ± 3.21 2.49 ± 2.92 2.30 (23) 0.03 0.96
Lf-Cb mg·mL−1 2.77 ± 1.26 2.96 ± 2.68 0.96 (20.8) 0.35 0.30
Lf-SRb µg·min−1 6.54 ± 3.41 9.61 ± 3.88 0.90 (24) 0.38 0.37
Variable URTI + URS Healthy + asymptomatic
carriers
t (df) P d
Lys-Cb mg·mL−1 0.36 ± 1.62 0.58 ± 2.44 2.69 (27.2) 0.012 0.77
Lys-SRb µg·min−1 0.90 ± 3.02 1.83 ± 3.16 2.30 (30) 0.10 0.70
Lf-Cb mg·mL−1 2.74 ± 1.23 2.72 ± 2.41 0.57 (27.4) 0.57 0.21
Lf-SRb µg·min−1 6.07 ± 3.72 8.27 ± 3.48 0.72 (31) 0.48 0.30
One sample in the healthy group was out of range of the assay for Lys-C and not included in the analysis of Lys. C, concentration; SR, secretion rate; t, t-statistic; df, degrees of freedom;
d, Cohen’s d effect size. amean ± SD; bgeometric mean ± geometric SD factor. Bold text indicates p < 0.05.
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FIGURE 1 | Tear lysozyme (Lys) and lactoferrin (Lf) in participants with
pathogen-confirmed upper respiratory tract infection compared to healthy,
pathogen-free controls. Pooled data from three time points in the URTI group
(1 week before, during and after recovery from URTI, n = 9 × 3, closed
symbols) and two time points in the Healthy group (beginning and end of
3-week monitoring period, n = 17 × 2, open symbols). •, non-contact lens
wearers;N, contact lens wearers; C, concentrations; SR, secretion rates. (A)
Lys-C; (B) Lf-C; (C) Lys-SR and (D) Lf-SR. Data are geometric mean and SD
factor. Difference between groups: *P < 0.05, **P < 0.01, ***P < 0.001.
URTI) compared to healthy participants, with large Cohen’s
d effect sizes (Table 2). However, there were no significant
differences in tear Lf between participants with URTI and healthy
participants (Table 2). When all symptomatic (URTI + URI)
or asymptomatic participants (healthy + asymptomatic carriers)
were included in the analysis, the effect sizes between the groups
were smaller but still “medium” (Table 2).
Comparison of the grand mean of tear AMP concentrations
and secretion rates in healthy participants (n = 17) at two time-
points (pre- and post-monitoring), vs. participants with URTI (n
= 9) at three time points (pre-URTI, during URTI and recovery)
revealed that tear Lys-C was lower in the URTI group throughout
the monitoring period (Figure 1A; P = 0.002, d = 0.85).
Similarly, tear Lys-SR was lower in participants who reported
URTI throughout the study (Figure 1C; P < 0.001, d = 0.99). A
smaller difference in the grand mean of tear Lf-SR between URTI
and healthy participants was also found (Figure 1D; P = 0.019,
d = 0.62). There was no significant difference in Lf-C between
groups (Figure 1B, P = 0.132, d = 0.38).
Repeated-measures analysis of the nine participants who
reported pathogen-confirmed URTI revealed no differences in
tear Lys or Lf either before or during URTI compared to when the
FIGURE 2 | Tear lysozyme (Lys) and lactoferrin (Lf) 1 week before (Pre-URTI),
during (URTI) and 4 weeks after (Recovery) an episode of upper respiratory
tract infection. No differences in tear Lys or Lf were observed before or during
URTI compared to recovery. Concentration data are mean and SD, secretion
rates are geometric mean and SD factor. •, non-contact lens wearers;N,
contact lens wearers; C, concentrations; SR, secretion rates. (A) Lys-C; (B)
Lf-C; (C) Lys-SR and (D) Lf-SR.
FIGURE 3 | Tear lysozyme (Lys, A) and lactoferrin (Lf, B) secretion rates (SR)
measured across three time points in symptomatic participants (URTI + URS,
n = 11). Both tear Lys-SR and Lf-SR were significantly lower in contact lens
wearers (P = 0.018 and P = 0.008, respectively). Data are geometric mean
and SD factor.
same participants had been symptom-free for 4 weeks (Figure 2).
These results remained if the two participants who reported
symptoms but did not have positive viral cultures were also
included (data not shown).
Across the three time points combined in the symptomatic
group (URTI + URS), tear Lys-SR and Lf-SR were also lower
in contact lens wearers than non-contact lens wearers (12 vs. 21
time-points from 4 vs. 7 participants; P = 0.018 and P = 0.008
respectively, Figure 3).
Subsequently, to examine whether the results displayed in
Figure 1 were an artifact of the differing proportions of contact
lens wearers in each group, the analyses were repeated with
contact lens wearers excluded. When contact lens wearers were
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FIGURE 4 | Tear lysozyme (Lys, A) and lactoferrin (Lf, B) secretion rate (SR) responses to 120min exercise at ∼65% VO2peak (EX, closed circles) compared to seated
rest control (REST, open circles). Significant difference between time points on EX: a, vs. Pre, P < 0.05; b, vs. Pre, P < 0.01; c, vs. Post, P < 0.001. Data are
geometric mean and SD factor.
FIGURE 5 | Influence of exercise-induced dehydration, followed by overnight fluid restriction (DEH) compared to euhydrated control (EUH) on tear lysozyme
concentration (Lys-C, A) and lactoferrin concentration (Lf-C, B). Data are mean and SD. Main effect of time: *P < 0.05, **P < 0.01.
excluded from the analysis, significant differences remained
between the URTI and Healthy groups for Lys-C (P = 0.005)
and Lys-SR (P = 0.012) but not for Lf-SR (P = 0.223) (data
not shown).
Study 2: Influence of Prolonged Exercise
on Tear AMPs
Tear Lf and Lys concentration were not influenced by exercise
(data not shown). However, there was a time × trial interaction
for Lf-SR [F(4, 48) = 3.594, P = 0.012] and Lys-SR [F(4, 48) =
3.521, P = 0.013). Post-hoc analyses revealed that Lf and Lys
secretion rates were significantly reduced at 30min and 1 h
post-EX compared to pre- and immediately post-EX (Figure 4).
Compared to pre-EX values, Lf-SR was 42% lower at 30min post-
EX (d = 0.91) and 1 h post-EX (d = 0.93). Similarly, Lys-SR was
reduced by 49% at 30min post-EX (d = 0.80) and by 48% at 1 h
post-EX (d = 0.81) vs. pre-EX. There were no differences in tear
Lf and Lys-SR between any of the time points on the REST trial.
Study 3: Influence of Dehydration on Tear
AMPs
There was no influence of dehydration on tear AMP
concentrations or secretion rates. However, we observed a
main effect of time for Lys-C [F(3, 36) = 5.108, P = 0.0048]
and Lf-C [F(3, 36) = 3.539, P = 0.024]. Post-hoc comparisons
revealed that Lys-C and Lf-C were lower at 08:00 (∼3% BML)
than at 16:30 on day 1 (∼2% BML; P < 0.05; Figure 5). There
were no main effects of time for tear AMP secretion rates (data
not shown).
DISCUSSION
This aim of this series of studies was to evaluate tear AMPs as
clinically relevant biomarkers of immune function. Our primary
aim in study 1 was to explore the clinical relevance of tear
AMPs as markers of host defense, by investigating whether AMP
secretion rates were associated with subsequent presentation of
upper respiratory symptoms. We found that the participants
who reported URTI during the monitoring period had lower
tear AMP concentrations and secretion rates across all time
points combined compared to those who remained healthy.
These findings suggest that tear AMPs may be clinically relevant
biomarkers of host defense. However, no change in tear AMP
concentrations or secretion rates occurred before or during
illness compared to when the same participants were illness-
free, suggesting these markers have less potential to monitor
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week-to-week changes in immunity but may potentially be useful
to determine immune status over a longer time-period. We
previously demonstrated that tear secretory IgA has utility to
detect changes in immune status in the days before presentation
of URI (34). Thus, we suggested acute perturbations in tear IgA
may have utility to predict susceptibility to URTI within the
forthcoming days. On the other hand, the findings from this
study suggest that tear Lf and Lys may be better suited to identify
individuals who are illness-prone or chronically susceptible to
URTI. Future studies may therefore wish to investigate whether
tear Lys and Lf are chronically lower in participants prone to
recurrent URTI over a longer time-period.
Prolonged exercise typically causes brief post-exercise
immunomodulatory effects (41). Whether or not such responses
may be detrimental to immune competence, via the so-called
“open window” hypothesis, has been recently reviewed elsewhere
(16). Focusing specifically on mucosal AMPs, previous studies
have demonstrated no change (37, 42, 43), an increase (44, 45) or
a decrease (46) in salivary AMP secretion rates after prolonged
exercise. Decreases in salivary AMP concentration that have been
observed post-exercise may be offset by increases in flow rate
(42, 47). In study 2, we saw no change in tear AMP concentration
or secretion rate immediately post-exercise, but observed large
reductions in tear Lf and Lys secretion rates between 30min
and 1 h post-exercise. Since tear AMP concentrations were not
affected by prolonged exercise, this response likely occurred as a
result of downregulation of lacrimal gland secretory activity, that
is, a reduction in the output of proteins, water and electrolytes
(27). A single bout of prolonged exercise is known to exhibit a
biphasic immune response characterized by an acute increase
in total lymphocyte count followed by a decrease to below
pre-exercise levels in the post-exercise recovery period (48, 49).
Elevated cortisol post-exercise has been shown to maintain
an increase in neutrophil counts for up to 2 h post-exercise,
accompanied by an increased generation of reactive oxygen
species (50). Prolonged exercise may also increase a range of
circulating cytokines and chemokines including IL-6, IL-8, IL-10,
and TNF-A for up to 3 h post-exercise (48, 51, 52). Although we
did not measure circulating hormones, leukocytes or cytokines
in the present study, in-vitro studies have demonstrated that
oxidative stress, steroid hormones and pro-inflammatory
cytokines can inhibit lacrimation (31, 32). Since lacrimal gland
activity is primarily regulated by the autonomic nervous system,
alterations to autonomic balance during the post-exercise
recovery period may also have directly influenced tear output.
Thus, while the mechanism by which tear AMP availability was
reduced post-exercise is not clear from this study, our findings
illustrate a transient decrease in lacrimal gland secretion and
thus availability of AMPs at the ocular surface during the post-
exercise recovery period that led to a localized, albeit temporary
reduction in immune competence.
Since a majority of studies report no influence of mild
dehydration on cellular immune parameters (53), mild
dehydration (1–3% BML) has often been viewed as confounding
variable (as opposed to a stressor) when considering mucosal
responses to exercise. Whilst one study reported temporary
reductions in salivary AMP secretion rates following mild
exercise-induced dehydration (47), another study reported no
influence of fluid restriction-induced dehydration on AMP
secretion rates post-exercise (38). As expected in study 3, we
found no evidence to suggest dehydration influences tear AMP
concentration or secretion rate, and can thus conclude that tear
AMPs are robust to alterations in hydration status.
In study 1 we did not find any evidence of diurnal variation
between samples collected mid-morning and mid-afternoon in
healthy participants, but in study 3 we observed that tear AMP
concentrations were lower first-thing in the morning (08:00)
compared to late afternoon (16:30) in the same participants.
This diurnal variation was not seen in tear AMP secretion rates.
Whilst we did not specifically design either study to investigate
diurnal variation, previous studies have reported that tear Lys has
a tendency to be lower in the morning and higher in the evening,
as seen in study 3 (54). This could perhaps be a consequence
of lower lacrimal gland secretion at night, leading to a lower
proportion of tear Lys and Lf in the closed-eye state (55) which
may take some time to resolve after waking.
In study 1 we also saw that tear AMP secretion rates were
lower in contact lens wearers, and that there was a higher
proportion of contact lens wearers in the URTI group (4/9) than
the pathogen-free, healthy group (3/17). This is consistent with
previous studies that have shown increased tear osmolarity and
lower tear volume in contact lens wearers (56). Although contact
lens wear is an established risk factor for microbial keratitis (57),
to our knowledge no studies have investigated whether contact
lens wear increases URTI incidence, which is feasible since the eye
is a portal for inoculation of viral pathogens such as influenza (4).
It would therefore be interesting to further explore whether the
use of contact lenses is in itself a risk factor for URTI, for example
by reducing the secretion rates of tear AMPs or by facilitating
transmission of pathogens via the ocular surface.
Strengths and Limitations
A strength of this series of studies is the thorough experimental
approach employing both well-controlled repeated-measures
crossover designs to explore the effect of dehydration and
exercise on tear AMPs as well as the prospective cohort design
of study 1. In study 1, given the geographic proximity of the
participants to each other, we can assume that that most, if
not all, participants will have been exposed to URTI during
the monitoring period. We also had a good representation of
URTI in the sample with almost one-third of participants self-
reporting URI within the monitoring period, of whom nine of
eleven returned positive virology tests. This is a higher rate
of positive tests than in previous studies in athletes that have
typically identified pathogens in only 30–40% of self-reported
URI episodes (40, 58). As only a limited panel of bacteria and
viruses was used, it is possible that the two participants who
reported symptoms but with a negative virology test could also
have contracted an infection that was not identified by the
diagnostic test, or that the symptoms arose from a non-infectious
origin. Thus, we argue that studying both the populations who
reported episodes of URI as a whole (symptomatic group)
as well as the sub-population who reported symptoms and
positive virology (URTI group) is pertinent to understanding the
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utility of Lf and Lys as biomarkers of illness risk. Nevertheless,
with our cohort of 40 participants, the statistical power of the
resulting URTI and Healthy groups was sufficient only to detect
large effects. Lifestyle variables such as alcohol and tobacco
intake, exercise and sleep were not controlled in study 1, so we
consider it a strength for the clinical relevance of tear AMPs
that we saw differences between the URTI and Healthy groups
in spite of the background “noise” of the variables that were
not controlled.
A potential limitation of the sampling technique and/or in
the use of tears to assess AMPs was the large variability in tear
flow rates. Although previous studies suggest that concentrations
of tear Lys and Lf are similar in unstimulated and reflex tears
(55, 59), there was substantial variability in tear flow rates both
between- and within-participants in all studies. Samples obtained
with high flow rates may therefore have led to high outliers in
AMP secretion rates. Additionally, there are some challenges
in measuring the flow rate of tears, since some of the initial
sample may be obtained from basal tears already residing on
the lower lid of the eye, a volume estimated at around 7 µL
(26). However, it is impractical to drain the eye of tears before
beginning collection, as may be achieved to some extent in saliva
sampling by swallowing before commencing sample collection.
Conversely, we had difficulty obtaining sufficient volumes of
tear sample from a few participants, leading to longer collection
times. Whether these participants were not producing tears or
that the tears were difficult to access remains unclear. This may
also apply to contact lens wearers, in whom AMP secretion
rates were lower within the participants who reported URS
in study 3. Several of these constraints could be overcome by
using AMP concentrations as primary outcome variables, as
they are less affected by tear flow rates. On the other hand, it
is highly possible the availability of tear AMPs at the ocular
surface is more important for host defense, indicated by secretion
rates. Indeed, in the present study, only AMP secretion rates
were significantly lower following prolonged exercise; a response
that we may expect to observe in a clinically relevant immune
biomarker. There is also potential for nanotechnology to facilitate
the development of continuous monitoring devices, such as
“smart” contact lenses (33, 60) or point-of-care devices that
could improve the ability to measure tear flow as well as tear
fluid composition.
CONCLUSIONS
This series of studies set out to evaluate the potential clinical
relevance and utility of the tear fluid AMPs Lf and Lys as
minimally-invasive biomarkers of mucosal immune competence.
We observed that tear Lys concentration and Lys and Lf
secretion rates were lower in participants who reported an
episode of URTI within a 3-week monitoring period, compared
to individuals who remained healthy. Tear AMP secretion rates
were also temporarily reduced 30min to 1 h after prolonged
treadmill exercise and were robust to any confounding effect of
dehydration on flow rates at mucosal surfaces. We also found
that tear AMP secretion rates were lower in contact lens wearers,
albeit among a small cohort. Thus, our observations serve to
highlight avenues for further study but follow-up studies will
be important to verify these preliminary findings. Collectively,
this series of studies provides an initial demonstration that
tear AMPs, especially secretion rates, may be clinically relevant
markers of mucosal immune competence. It is possible that
progress in nanotechnology and microfluidics will facilitate
development of devices to improvemeasurement of tear flow and
composition in the future.
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